About RWEOne

Empowering Pharma with AI-Driven Clinical Evidence

RWEOne is a specialized clinical technology and services partner empowering global pharmaceutical companies to conduct end-to-end Real-World Evidence (RWE) and Real-World Data (RWD) studies. Backed by 12+ years of clinical expertise, RWEOne integrates artificial intelligence with existing healthcare data endpoints to compress clinical study lifecycles, validate data in real-time, and drive confident regulatory and commercial decisions.

What is RWEOne?

Specialists in End-to-End Evidence Generation

RWEOne is more than a technology vendor — we are a specialized clinical technology and services partner dedicated to the global pharmaceutical industry. Our unique offering combines a purpose-built AI technology platform with deep in-house clinical operations, biostatistics, and regulatory expertise.

We focus exclusively on Real-World Evidence (RWE) and Real-World Data (RWD) studies across every phase of the product lifecycle — from early Phase 1 feasibility through post-market Phase 4 surveillance and lifecycle evidence generation.

The RWEOne platform delivers Electronic Data Capture (EDC) with dynamic eCRF building, CDISC/CDASH compliance by default, AI-driven data validation, RabbitMQ-based immutable audit trails, and real-time analytics — all in a single, unified ecosystem designed to eliminate vendor fragmentation.

12+
Years Experience
500+
Studies Delivered
50+
Countries Served
15+
Therapeutic Areas
Why Global Pharma Chooses RWEOne

Built to Deliver Trusted Evidence at Speed

Every study we run combines a mature global network, AI-driven technology, and a compliance-first architecture engineered for regulatory-grade results.

Expansive Global Site Network

Accelerate investigator onboarding and patient access. Tap into our established global connections across diverse therapeutic areas to capture high-fidelity, representative data.

01 · Core Pillar

AI-Powered Trial Acceleration

The future of pharma relies on speed without compromising accuracy. Our AI-driven validations automate the heaviest data burdens, reducing the time and cost of moving from Phase 1 to post-market Phase 4.

02 · Core Pillar

Uncompromising Compliance & Security

Stay audit-ready from day one. We ensure absolute data integrity with robust restricted sponsor access, digital CTA signatures, and immutable event tracking.

03 · Core Pillar

Unified, End-to-End Execution

Eliminate vendor fragmentation. From study design to advanced analytics, manage your entire RWE lifecycle within a single, interconnected ecosystem.

04 · Core Pillar
Our Core Values

Principles That Guide Every Study We Run

Evidence First

Every decision is grounded in rigorous methodology and scientific integrity.

Compliance By Design

GxP, 21 CFR Part 11, GDPR — baked into every layer of our platform and process.

Speed Without Compromise

AI-driven workflows accelerate timelines while upholding the highest data quality standards.

Partner Mentality

We embed with your team — an extension of your clinical, medical, and commercial functions.

Our Journey

Over a Decade of Clinical Innovation

2013

Founded

RWEOne established with a mission to transform real-world evidence generation for pharma.

Milestone 01/05

RWEOne established with a mission to transform real-world evidence generation for pharma.

2016

Global Expansion

Expanded site network across 30+ countries and launched proprietary eCRF platform.

Milestone 02/05

Expanded site network across 30+ countries and launched proprietary eCRF platform.

2019

AI Integration

First AI-driven validation engines deployed, reducing query resolution time by 60%.

Milestone 03/05

First AI-driven validation engines deployed, reducing query resolution time by 60%.

2022

RWD Lake Launch

Introduced comprehensive Real-World Data lake architecture for continuous evidence generation.

Milestone 04/05

Introduced comprehensive Real-World Data lake architecture for continuous evidence generation.

2025

500+ Studies Delivered

Celebrated 500+ successful studies and 50+ country coverage across all major therapeutic areas.

Milestone 05/05

Celebrated 500+ successful studies and 50+ country coverage across all major therapeutic areas.

Leadership Team

Seasoned Experts in Clinical & Regulatory Strategy

Our cross-functional leadership team combines decades of pharmaceutical industry experience across clinical operations, technology, biostatistics, and regulatory affairs.

Dr. Sarah Chen

Chief Executive Officer

MD, MPH — 20+ yrs pharma clinical strategy

James Whitmore

Chief Technology Officer

MS Computer Science — Ex-Oracle Health, EDC platform architect

Dr. Marcus Rivera

Chief Scientific Officer

PhD Biostatistics — Led 200+ Phase 1-4 studies

Elena Kowalski

Head of Regulatory Affairs

JD, Regulatory Law — 15+ yrs FDA/EMA submissions

Get Started Today

Ready to modernize your clinical evidence strategy?

See how RWEOne can compress your trial timelines and automate your data workflows. Book a custom demo tailored to your therapeutic area and Phase 1-4 objectives.

What to expect on your demo:

  • A live walkthrough of our dynamic eCRF builder.
  • A showcase of our AI-driven validation engines in action.
  • A tailored discussion on mapping your specific Phase 1-4 endpoints.

Request Your Platform Demo

Compliance-first.Every engagement is covered by mutual NDA. All data pipelines and platform workflows are validated for use in GxP and 21 CFR Part 11 contexts.